Drug Trial Radar · NCT03644264
PA21 Safety and Efficacy in Adult Chinese Subjects
Last checked: Nov 20, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
286
Actual
Start
Aug 31, 2018
Primary completion
Aug 21, 2020
Study completion Aug 21, 2020
Sponsor
- Lead sponsor
- Vifor Fresenius Medical Care Renal PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment.
Conditions
- Chronic Kidney Disease Requiring Chronic Dialysis
- Hyperphosphatemia
Interventions
PA21Drug
sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.
sevelamer carbonateDrug
sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serum phosphorus (mmol/l )Time frame: baseline and 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Southern Medical University Nanfang Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.